News

Nvidia Unveils Key Healthcare AI Partnerships at JPM25

• By John K. Waters
• 01/15/2025

Nvidia announced a series of groundbreaking collaborations at the J.P. Morgan Healthcare Conference in San Francisco on Monday. These partnerships, spanning healthcare, life sciences, and biopharma, aim to accelerate the adoption and scalability of AI models across the sector, driving advancements in diagnostics, drug discovery, and precision medicine.

A highlight of Nvidia’s announcement is its partnership with Mayo Clinic to advance pathology foundation models. Leveraging Mayo Clinic’s digital pathology platform—which includes 20 million whole-slide images and 10 million associated patient records—the collaboration will utilize Nvidia’s DGX Blackwell AI systems and Monai, a healthcare imaging platform, to streamline development.

"Our ultimate goal is to create a human digital twin," said Kimberly Powell, vice president and general manager of healthcare at Nvidia, during a press briefing. "This dynamic digital representation—incorporating medical imaging, pathology, health records, and wearables—will be a cornerstone for applications in drug discovery and diagnostic medicine."

Nvidia’s partnership with IQVIA, a leader in life sciences analytics and clinical research, focuses on leveraging its AI foundry service to develop foundation models. IQVIA aims to deploy AI agents—autonomous models designed to perform specific tasks—to its global customer base of over 10,000 healthcare and life sciences organizations.

"IQVIA has a unique dataset of 64 petabytes of proprietary data representing over a billion anonymized patients from 100 countries," Powell said. Nvidia’s AI foundry service, which includes models, software, and expert consulting, will accelerate the development and deployment of these AI agents.

Agent AI can not only perceive, but it can reason, plan, and even take action," Powell said, highlighting the transformative potential of these technologies.

In the biopharma space, Nvidia announced a collaboration with Illumina, a global leader in DNA sequencing. The partnership will leverage Nvidia’s computing and AI toolsets to enhance Illumina’s multiomics analysis capabilities—a technology that integrates data from genomes, transcriptomes, proteomes, and more.

"We’re going to unlock new markets for genomics by making genomics insights much more accessible and impactful," Powell said. The foundation models developed through this partnership will advance drug discovery and precision medicine.

Nvidia’s collaboration with Arc Institute, a research organization at the intersection of biology and machine learning, aims to create generalized foundation models for biology. Using Nvidia BioNeMo and DGX Cloud, the partnership will focus on DNA, RNA, and protein research.

"Our resulting work will be shared openly through BioNeMo to truly democratize large-scale biomedical research," Powell said.

Nvidia’s partnerships underscore its commitment to transforming healthcare through AI, the company said. The company plans to share the results of these collaborations throughout the year, signaling a new era of innovation in medical research, diagnostics, and therapeutics.

"These collaborations are setting the stage for unprecedented advancements in healthcare and life sciences," Powell said. "We’re excited to be at the forefront of this transformation."